<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="Google Web Designer 5.1.1.0611" name="generator"/>
<meta content="Banner 3.0.0" name="template"/>
<meta content="gwd-dv360" name="environment"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link data-exports-type="gwd-page" data-version="12" href="gwdpage_style.css" rel="stylesheet"/>
<link data-exports-type="gwd-pagedeck" data-version="12" href="gwdpagedeck_style.css" rel="stylesheet"/>
<link data-exports-type="gwd-image" data-version="12" href="gwdimage_style.css" rel="stylesheet"/>
<link data-exports-type="gwd-taparea" data-version="6" href="gwdtaparea_style.css" rel="stylesheet"/>
<link data-exports-type="gwd-google-ad" data-version="5" href="gwdgooglead_style.css" rel="stylesheet"/>
<style id="gwd-lightbox-style" type="text/css">
    .gwd-lightbox {
      overflow: hidden;
    }
  </style>
<style id="gwd-text-style" type="text/css">
    ::-webkit-scrollbar {
      width: 4px;
    }
    ::-webkit-scrollbar-track {
      border-left: 2px solid rgb(237, 237, 237);
      border-right: 2px solid rgb(237, 237, 237);
      background-color: rgb(237, 237, 237);
    }
    ::-webkit-scrollbar-thumb {
      background-color: rgb(149, 149, 149);
    }
    p {
      margin: 0px;
      color: rgb(88, 89, 91);
    }
    h1 {
      margin: 0px;
    }
    h2 {
      margin: 0px;
    }
    h3 {
      margin: 0px;
    }
    sup {
      position: relative;
      font-size: 60%;
      line-height: 0;
      vertical-align: baseline;
      top: -0.4em;
    }
    .font-purple {
      color: rgb(102, 45, 145);
    }
    .font-green {
      color: rgb(0, 165, 157);
    }
  </style>
<style type="text/css">
    html, body {
      width: 100%;
      height: 100%;
      margin: 0px;
    }
    .gwd-page-container {
      position: relative;
      width: 100%;
      height: 100%;
    }
    .gwd-page-content {
      background-color: transparent;
      transform: perspective(1400px) matrix3d(1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1);
      transform-style: preserve-3d;
      position: absolute;
    }
    .gwd-page-wrapper {
      background-color: rgb(255, 255, 255);
      position: absolute;
      transform: translateZ(0px);
    }
    .gwd-page-size {
      width: 300px;
      height: 600px;
    }
    .frame-txt {
      text-align: right;
      font-family: Arial;
      font-size: 16px;
      color: rgb(198, 12, 70);
    }
    .frame2-txt {
      position: absolute;
      opacity: 0;
      top: 68px;
      left: 128px;
    }
    .frame3-txt {
      position: absolute;
      opacity: 0;
      top: 68px;
      left: 70px;
    }
    .isi-area {
      position: absolute;
      border-top: 1px solid rgb(232, 232, 232);
      font-family: Arial, sans-serif;
      font-size: 10px;
      padding: 5px;
      overflow-y: scroll;
      opacity: 1;
      left: 0px;
      width: 290px;
      height: 190px;
      top: 400px;
    }
    .isi-narrow {
      width: 200px;
    }
    .isi-area p {
      margin: 0px 0px 5px;
    }
    .isi-area p.text-indent-bullets {
      text-indent: -6px;
      margin-left: 6px;
    }
    .isi-area p.text-indent-nobullets {
      margin-left: 6px;
    }
    .isi-area p.border-top {
      border-top: 1px solid black;
      margin-top: 12px;
      padding-top: 12px;
    }
    .warning-border {
      border: 1px solid rgb(1, 1, 1);
      padding: 6px 6px 0px;
      margin-bottom: 7px;
    }
    .janssen-logo {
      width: 83px;
      height: 36px;
      margin-top: 10px;
      margin-bottom: 10px;
    }
    .link {
      text-decoration: underline;
      cursor: pointer;
    }
    .footer {
      position: absolute;
      width: 300px;
      height: 30px;
      left: 0px;
      opacity: 0;
      top: 220px;
    }
    .logo {
      position: absolute;
      width: 92px;
      height: 33px;
      opacity: 0;
      top: 19px;
      left: 192px;
    }
    .photo {
      position: absolute;
      width: 253px;
      height: 253px;
      opacity: 0;
      transform-style: preserve-3d;
      top: 140px;
      left: 128px;
      transform: translate3d(76px, 106px, 0px);
    }
    .footer-pi-link {
      position: absolute;
      width: 300px;
      left: 0px;
      font-family: Arial;
      text-align: center;
      text-decoration: underline;
      font-weight: bold;
      font-size: 9px;
      opacity: 1;
      top: 103px;
    }
    .clickTag-learn {
      position: absolute;
      width: 300px;
      height: 133px;
      left: 0px;
      top: 0px;
    }
    .clickTag4-footer {
      position: absolute;
      left: 0px;
      width: 190px;
      height: 17px;
      top: 380px;
    }
    .gwd-sup-1mnz {
      font-family: Arial;
      font-size: 7.2px;
      text-align: left;
    }
    .gwd-div-1buh {
      width: 300px;
      height: 600px;
    }
    .gwd-div-11o7 {
      width: 300px;
      height: 600px;
    }
    .gwd-image-vluy {
      display: block;
      position: absolute;
      top: 413px;
      width: 80px;
      height: 52.29px;
      left: 210px;
    }
    .gwd-image-1n67 {
      display: block;
      position: absolute;
      width: 102px;
      height: 25.37px;
      left: 191px;
      top: 368px;
      opacity: 0;
    }
    .gwd-taparea-16yv {
      display: block;
      left: 0px;
      position: absolute;
      top: 1px;
      width: 300px;
      transform-origin: 150px 51.5px 0px;
      height: 398px;
    }
    .gwd-ul-z11u {
      color: rgb(255, 255, 255);
      font-family: Arial;
      font-size: 8px;
      height: 33.8125px;
      left: 9px;
      margin-bottom: 7px;
      position: absolute;
      top: 154px;
      width: 183.083px;
    }
    .gwd-a-1sxq {
      font-family: Arial;
      font-size: 8px;
    }
    .fade-bkg {
      display: block;
      height: 400px;
      left: 0px;
      position: absolute;
      top: 0px;
      width: 300px;
      transform-origin: 149.99px 199.986px 0px;
    }
    .gwd-image-1n7v {
      display: block;
      height: 287px;
      left: 0px;
      position: absolute;
      top: 0px;
      width: 300px;
    }
    @keyframes gwd-gen-1soagwdanimation_gwd-keyframes {
      0% {
        opacity: 0;
        animation-timing-function: ease-out;
      }
      74.1379% {
        opacity: 0;
        animation-timing-function: ease-out;
      }
      100% {
        opacity: 1;
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1soagwdanimation {
      animation: gwd-gen-1soagwdanimation_gwd-keyframes 5.8s linear 0s 1 normal forwards running;
    }
    @keyframes gwd-gen-1159gwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(92px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      88.4058% {
        transform: translate3d(92px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(331px, 0px, 0px);
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1159gwdanimation {
      animation: gwd-gen-1159gwdanimation_gwd-keyframes 6.9s linear 0s 1 normal forwards running;
    }
    .link-desc {
      color: rgb(255, 255, 255);
      display: block;
      font-family: Arial;
      font-size: 8px;
      height: 10.9792px;
      left: 8px;
      position: absolute;
      top: 356px;
      width: 141.979px;
      transform: matrix(1, 0, 0, 1, 0, 0);
      transform-origin: 0px 0px 0px;
      transform-style: preserve-3d;
    }
    .gwd-br-k2oh {
      color: rgb(255, 255, 255);
      font-family: Arial;
      font-size: 8px;
    }
    .jsn-logo {
      display: block;
      left: 18px;
      position: absolute;
      top: 324px;
      transform-style: preserve-3d;
      width: 205px;
      height: 51px;
      opacity: 0;
      transform: translate3d(174px, 44px, 0px);
    }
    .learn-more {
      display: block;
      height: 42px;
      left: -330px;
      position: absolute;
      top: 235px;
      width: 225px;
      transform-style: preserve-3d;
      transform: translate3d(92px, 0px, 0px);
    }
    .img-2 {
      display: block;
      height: 800px;
      left: -438px;
      position: absolute;
      top: 0px;
      width: 1200px;
      transform-style: preserve-3d;
    }
    .rec-1 {
      display: block;
      height: 399px;
      left: -584px;
      position: absolute;
      top: 0px;
      width: 565px;
      transform-origin: 274.248px 199.578px 0px;
      transform-style: preserve-3d;
      font-size: 16px;
    }
    .txt-1 {
      display: block;
      left: -417px;
      position: absolute;
      top: 200px;
      transform-style: preserve-3d;
      font-size: 16px;
      transform: translate3d(0px, 0px, 0px);
      width: 156px;
      height: 70.84px;
    }
    .darza-logo {
      display: block;
      height: 58px;
      left: 199px;
      position: absolute;
      top: 413px;
      width: 89px;
    }
    @keyframes gwd-gen-ol32gwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(758px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      74.1379% {
        transform: translate3d(758px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(0px, 0px, 0px);
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-ol32gwdanimation {
      animation: gwd-gen-ol32gwdanimation_gwd-keyframes 5.8s linear 0s 1 normal forwards running;
    }
    .gwd-rect-i4bu {
      position: absolute;
      height: 201px;
      top: 400px;
      box-sizing: border-box;
      border-width: 1px;
      border-style: solid;
      border-color: transparent;
      background-clip: content-box;
      background-color: rgb(255, 255, 255);
      width: 300px;
      left: -1px;
    }
    @keyframes gwd-gen-1p04gwdanimation_gwd-keyframes {
      0% {
        opacity: 0;
        animation-timing-function: ease-out;
      }
      80.3571% {
        opacity: 0;
        animation-timing-function: ease-out;
      }
      100% {
        opacity: 1;
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1p04gwdanimation {
      animation: gwd-gen-1p04gwdanimation_gwd-keyframes 5.6s linear 0s 1 normal forwards running;
    }
    @keyframes gwd-gen-1d35gwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(0px, 229px, 0px);
        opacity: 0;
        animation-timing-function: ease-out;
      }
      76% {
        transform: translate3d(0px, 229px, 0px);
        opacity: 0;
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(0px, 229px, 0px);
        opacity: 1;
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1d35gwdanimation {
      animation: gwd-gen-1d35gwdanimation_gwd-keyframes 2.5s linear 0s 1 normal forwards running;
    }
    .gwd-p-p45r {
      width: 183.08px;
      transform-style: preserve-3d;
      transform: translate3d(0px, 229px, 0px);
      opacity: 0;
    }
    @keyframes gwd-gen-1hkagwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(0px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      22.4138% {
        transform: translate3d(430px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      74.1379% {
        transform: translate3d(430px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(-10px, 0px, 0px);
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1hkagwdanimation {
      animation: gwd-gen-1hkagwdanimation_gwd-keyframes 5.8s linear 0s 1 normal forwards running;
    }
    .gwd-div-40l1 {
      font-size: 16px;
    }
    @keyframes gwd-gen-nfj6gwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(0px, 0px, 0px);
        width: 156px;
        height: 70.84px;
        animation-timing-function: ease-out;
      }
      22.4138% {
        transform: translate3d(426px, 0px, 0px);
        width: 156px;
        height: 70.84px;
        animation-timing-function: ease-out;
      }
      74.1379% {
        transform: translate3d(426px, 0px, 0px);
        width: 156px;
        height: 70.84px;
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(-14px, 0px, 0px);
        width: 156px;
        height: 70.84px;
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-nfj6gwdanimation {
      animation: gwd-gen-nfj6gwdanimation_gwd-keyframes 5.8s linear 0s 1 normal forwards running;
    }
    .gwd-div-1n8b {
      font-size: 16px;
    }
    @keyframes gwd-gen-1pengwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(0px, 0px, 0px);
        animation-timing-function: linear;
      }
      22.4138% {
        transform: translate3d(0px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      43.1034% {
        transform: translate3d(425px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      74.1379% {
        transform: translate3d(426px, 0px, 0px);
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(-4px, 0px, 0px);
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1pengwdanimation {
      animation: gwd-gen-1pengwdanimation_gwd-keyframes 5.8s linear 0s 1 normal forwards running;
    }
    .gwd-image-kvl1 {
      display: block;
      font-size: 16px;
      height: 49px;
      left: -426px;
      position: absolute;
      top: 282px;
      width: 276px;
      transform-style: preserve-3d;
    }
    .gwd-div-1yi2 {
      font-size: 16px;
    }
    @keyframes gwd-gen-1a8dgwdanimation_gwd-keyframes {
      0% {
        transform: translate3d(560px, 0px, 0px);
        width: 261px;
        height: 91.18px;
        animation-timing-function: ease-out;
      }
      100% {
        transform: translate3d(2px, 0px, 0px);
        width: 261px;
        height: 91.18px;
        animation-timing-function: linear;
      }
    }
    #page1.gwd-play-animation .gwd-gen-1a8dgwdanimation {
      animation: gwd-gen-1a8dgwdanimation_gwd-keyframes 1.5s linear 4.3s 1 normal forwards running;
    }
    .gwd-image-1thf {
      display: block;
      font-size: 16px;
      left: 8px;
      position: absolute;
      top: 121px;
      transform-style: preserve-3d;
      width: 261px;
      height: 91.18px;
      transform: translate3d(560px, 0px, 0px);
    }
    .gwd-div-1j94 {
      font-size: 16px;
    }
  </style>
<script data-exports-type="googbase" data-source="googbase_min.js" data-version="4" src="googbase_min.js"></script>
<script data-exports-type="gwd_webcomponents" data-source="gwd_webcomponents_min.js" data-version="6" src="gwd_webcomponents_min.js"></script>
<script data-exports-type="gwd-page" data-source="gwdpage_min.js" data-version="12" src="gwdpage_min.js"></script>
<script data-exports-type="gwd-pagedeck" data-source="gwdpagedeck_min.js" data-version="12" src="gwdpagedeck_min.js"></script>
<script data-exports-type="gwd-google-ad" data-source="https://s0.2mdn.net/ads/studio/Enabler.js" src="https://s0.2mdn.net/ads/studio/Enabler.js"></script>
<script data-exports-type="gwd-image" data-source="gwdimage_min.js" data-version="12" src="gwdimage_min.js"></script>
<script data-exports-type="gwd-taparea" data-source="gwdtaparea_min.js" data-version="6" src="gwdtaparea_min.js"></script>
<script gwd-events="support" src="gwd-events-support.1.0.js" type="text/javascript"></script>
<script src="https://s0.2mdn.net/ads/studio/cached_libs/tweenlite_1.19.0_422f021fad4c20f20cf3640a06ac39e9_min.js" type="text/javascript"></script>
<script src="https://s0.2mdn.net/ads/studio/cached_libs/cssplugin_1.19.0_cfbff7d208ccfdbe176b9855af1eb1fa_min.js" type="text/javascript"></script>
<script src="https://s0.2mdn.net/ads/studio/cached_libs/scrolltoplugin_1.19.0_53288c1da14a1784cdf302f94d0116a7_min.js" type="text/javascript"></script>
<script src="https://s0.2mdn.net/ads/studio/cached_libs/timelinelite_1.19.0_13e3bd0e510d63fd5e5ef9bf9dac7017_min.js" type="text/javascript"></script>
<script gwd-events="handlers" type="text/javascript">
    window.gwd = window.gwd || {};
    gwd.scrollIsi = function(event) {
      setTimeout(function() {
        var isi = new TimelineLite();
        isi.to(document.querySelector('.gwd-isi'), 450, {
          delay: 6,
          scrollTo: {
            y: 'max'
          },
          ease: 'linear'
        });
      }, 3000);
    };
    gwd.auto_ClickTag_mainExitAction = function(event) {
      // GWD Predefined Function
      gwd.actions.gwdGoogleAd.exit('gwd-ad', 'mainExit', 'http://darzalexhcp.com', true, true, 'page1');
    };
    gwd.auto_ClickTag_PIAction = function(event) {
      // GWD Predefined Function
      gwd.actions.gwdGoogleAd.exit('gwd-ad', 'PI Link', 'http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf', true, true, 'page1');
    };
  </script>
<script gwd-events="registration" type="text/javascript">
    // Support code for event handling in Google Web Designer
     // This script block is auto-generated. Please do not edit!
    gwd.actions.events.registerEventHandlers = function(event) {
      gwd.actions.events.addHandler('document.body', 'adinitialized', gwd.scrollIsi, false);
      gwd.actions.events.addHandler('clickTag-mainExit', 'action', gwd.auto_ClickTag_mainExitAction, false);
      gwd.actions.events.addHandler('clickTag-PI', 'action', gwd.auto_ClickTag_PIAction, false);
    };
    gwd.actions.events.deregisterEventHandlers = function(event) {
      gwd.actions.events.removeHandler('document.body', 'adinitialized', gwd.scrollIsi, false);
      gwd.actions.events.removeHandler('clickTag-mainExit', 'action', gwd.auto_ClickTag_mainExitAction, false);
      gwd.actions.events.removeHandler('clickTag-PI', 'action', gwd.auto_ClickTag_PIAction, false);
    };
    document.addEventListener("DOMContentLoaded", gwd.actions.events.registerEventHandlers);
    document.addEventListener("unload", gwd.actions.events.deregisterEventHandlers);
  </script>
<script data-exports-type="gwd-google-ad" data-source="gwdgooglead_min.js" data-version="5" src="gwdgooglead_min.js"></script>
</head>
<body>
<gwd-google-ad id="gwd-ad" polite-load="">
<gwd-metric-configuration>
<gwd-metric-event event="tapareaexit" exit="Exit" metric="" source="clickTag-PI"></gwd-metric-event>
<gwd-metric-event event="tapareaexit" exit="Exit" metric="" source="clickTag-mainExit"></gwd-metric-event>
</gwd-metric-configuration>
<gwd-pagedeck class="gwd-page-container" id="pagedeck">
<gwd-page class="gwd-page-wrapper gwd-page-size gwd-lightbox gwd-div-11o7" data-gwd-height="600px" data-gwd-width="300px" id="page1">
<div class="gwd-page-content gwd-page-size gwd-div-1buh">
<gwd-image class="gwd-image-1n7v" data-gwd-tl-locked="" id="DARZALEX_Evolution_Sun_Darker_lores_copy" scaling="stretch" source="assets/DARZALEX_Evolution_Sun_Darker_lores copy.jpg"></gwd-image>
<gwd-image class="fade-bkg" data-gwd-tl-locked="" id="fade-bkg_1" scaling="stretch" source="assets/fade-bkg.png"></gwd-image>
<gwd-image class="rec-1 gwd-gen-1hkagwdanimation" id="purple1" scaling="stretch" source="assets/rectangle_1v2.png"></gwd-image>
<div class="gwd-animation-event event-1-animation" data-event-name="event-1" data-event-time="100"></div>
<gwd-image class="img-2 gwd-gen-ol32gwdanimation" id="rectangle_2v2" scaling="stretch" source="assets/shape_2v2.png"></gwd-image>
<svg class="gwd-rect-i4bu" data-gwd-shape="rectangle" id="isibkg"></svg>
<div class="isi-area gwd-isi gwd-gen-1kwzgwdanimation" id="isi-area">
<p>Indication</p>
<p>DARZALEX<sup>®</sup> is indicated for the treatment of adult patients with multiple myeloma:</p>
<ul><li>in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy</li>
<li>in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant</li>
<li>in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy</li>
<li>in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor</li>
<li>as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent</li>
</ul>
<p>IMPORTANT SAFETY INFORMATION</p>
<br/>
<h3 class="section">CONTRAINDICATIONS</h3><p>DARZALEX<sup>®</sup> (daratumumab) is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of the components of the formulation.</p>
<p>WARNINGS AND PRECAUTIONS</p>
<p>Infusion Reactions – DARZALEX<sup>®</sup> can cause severe and/or serious infusion reactions, including anaphylactic reactions. In clinical trials, approximately half of all patients experienced an infusion reaction. Most infusion reactions occurred during the first infusion and were Grade 1-2. Infusion reactions can also occur with subsequent infusions. Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX<sup>®</sup>. Prior to the introduction of post-infusion medication in clinical trials, infusion reactions occurred up to 48 hours after infusion. Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema, and pulmonary edema. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, and hypotension.</p>
<br/>
<p>Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt infusion for reactions of any severity and institute medical management as needed. Permanently discontinue therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion.</p>
<p>To reduce the risk of delayed infusion reactions, administer oral corticosteroids to all patients following DARZALEX<sup>®</sup> infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease.</p>
<p>Interference With Serological Testing – Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type are not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX<sup>®</sup>. Type and screen patients prior to starting DARZALEX<sup>®</sup>.</p>
<p>Neutropenia and Thrombocytopenia – DARZALEX<sup>®</sup> may increase neutropenia and/or thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to the manufacturer’s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX<sup>®</sup> dose delay may be required to allow recovery of neutrophils and/or platelets. No dose reduction of DARZALEX<sup>®</sup> is recommended. Consider supportive care with growth factors for neutropenia or transfusions for thrombocytopenia.</p>
<p>Interference With Determination of Complete Response – Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.</p>
<p>Adverse Reactions – The most frequently reported adverse reactions (incidence ≥20%) were: infusion reactions, neutropenia, thrombocytopenia, fatigue, asthenia, nausea, diarrhea, constipation, decreased appetite, vomiting, muscle spasms, arthralgia, back pain, pyrexia, chills, dizziness, insomnia, cough, dyspnea, peripheral edema, peripheral sensory neuropathy, bronchitis, pneumonia, and upper respiratory tract infection.</p>
<p>DARZALEX<sup>®</sup> in combination with lenalidomide and dexamethasone (DRd): The most frequent (≥20%) adverse reactions for newly diagnosed or relapsed refractory patients were, respectively, infusion reactions (41%, 48%), diarrhea (57%, 43%), nausea (32%, 24%), fatigue (40%, 35%), pyrexia (23%, 20%), upper respiratory tract infection (52%, 65%), muscle spasms (29%, 26%), dyspnea (32%, 21%), and cough (30%, 30%). In newly diagnosed patients, constipation (41%), peripheral edema (41%), back pain (34%), asthenia (32%), bronchitis (29%), pneumonia (26%), decreased appetite (22%), and peripheral sensory neuropathy (24%) were also reported. In newly diagnosed patients, serious adverse reactions (≥2% compared to Rd) were dehydration (2%), bronchitis (4%), and pneumonia (15%), and treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were leukopenia (35%), neutropenia (56%), and lymphopenia (52%). In relapsed/refractory patients, serious adverse reactions (≥2% compared to Rd) were pneumonia (12%), upper respiratory tract infection (7%), influenza (3%), and pyrexia (3%), and treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were neutropenia (53%) and lymphopenia (52%).</p>
<p>DARZALEX<sup>®</sup> in combination with bortezomib, melphalan, and prednisone (DVMP): The most frequently reported adverse reactions (≥20%) were upper respiratory tract infection (48%), infusion reactions (28%), and peripheral edema (21%). Serious adverse reactions (≥2% compared to the VMP arm) were pneumonia (11%), upper respiratory tract infection (5%), and pulmonary edema (2%). Treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were lymphopenia (58%), neutropenia (44%), and thrombocytopenia (38%).</p>
<p>DARZALEX<sup>®</sup> in combination with bortezomib and dexamethasone (DVd): The most frequently reported adverse reactions (≥20%) were peripheral sensory neuropathy (47%), infusion reactions (45%), upper respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral edema (22%), and dyspnea (21%). The overall incidence of serious adverse reactions was 42%. Serious adverse reactions (≥2% compared to Vd) were upper respiratory tract infection (5%), diarrhea (2%), and atrial fibrillation (2%). Treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were lymphopenia (48%) and thrombocytopenia (47%).</p>
<p>DARZALEX<sup>®</sup> in combination with pomalidomide and dexamethasone (DPd): The most frequent adverse reactions (&gt;20%) were fatigue (50%), infusion reactions (50%), upper respiratory tract infection (50%), cough (43%), diarrhea (38%), constipation (33%), dyspnea (33%), nausea (30%), muscle spasms (26%), back pain (25%), pyrexia (25%), insomnia (23%), arthralgia (22%), dizziness (21%), and vomiting (21%). The overall incidence of serious adverse reactions was 49%. Serious adverse reactions reported in ≥5% of patients included pneumonia (7%). Treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were anemia (30%), neutropenia (82%), and lymphopenia (71%).</p>
<p>DARZALEX<sup>®</sup> as monotherapy: The most frequently reported adverse reactions (≥20%) were infusion reactions (48%), fatigue (39%), nausea (27%), back pain (23%), pyrexia (21%), cough (21%), and upper respiratory tract infection (20%). The overall incidence of serious adverse reactions was 33%. The most frequent serious adverse reactions were pneumonia (6%), general physical health deterioration (3%), and pyrexia (3%). Treatment-emergent Grade 3-4 hematology laboratory abnormalities (≥20%) were lymphopenia (40%) and neutropenia (20%).</p>
<p>Please click here to see the full Prescribing Information.</p>
<p>cp-60862v2</p>
</div>
<gwd-image class="gwd-image-vluy" id="dara_logo" scaling="stretch" source="assets/daraLogo300.png"></gwd-image>
<gwd-image class="txt-1 gwd-gen-nfj6gwdanimation" id="txt-1" scaling="stretch" source="assets/text1_6.png"></gwd-image>
<gwd-image class="gwd-image-kvl1 gwd-gen-1pengwdanimation" id="new_approval" scaling="stretch" source="assets/new_approval.png"></gwd-image>
<gwd-image class="gwd-image-1thf gwd-gen-1a8dgwdanimation" id="text-2v2" scaling="stretch" source="assets/text2_6.png"></gwd-image>
<gwd-image class="learn-more gwd-gen-1159gwdanimation" id="learn_more" scaling="stretch" source="assets/learn_more.png"></gwd-image><span class="link-desc legal gwd-gen-1soagwdanimation" id="legal">© Janssen Biotech, Inc. 2019<br class="gwd-br-k2oh"/>
            All rights reserved. 07/19 cp-92833v1</span>
<p class="gwd-ul-z11u gwd-gen-1d35gwdanimation gwd-p-p45r" id="Pleaseclick_1">Please click <a class="gwd-a-1sxq" href="http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf" style="color:white">here</a> for full Prescribing Information. </p>
<gwd-image class="gwd-image-1n67 gwd-gen-1p04gwdanimation" id="janssen_logo" scaling="stretch" source="assets/janssen_logo_3.png"></gwd-image>
<gwd-taparea class="gwd-taparea-16yv" data-gwd-tl-hidden="" id="clickTag-mainExit"></gwd-taparea>
<gwd-taparea class="clickTag4-footer" data-gwd-tl-hidden="" id="clickTag-PI"></gwd-taparea>
</div>
</gwd-page>
</gwd-pagedeck>
<gwd-exit metric="mainExit" url="http://darzalexhcp.com"></gwd-exit>
<gwd-exit metric="PI Link" url="http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf"></gwd-exit>
</gwd-google-ad>
<script id="gwd-init-code" type="text/javascript">
    (function() {
      var gwdAd = document.getElementById('gwd-ad');

      /**
       * Handles the DOMContentLoaded event. The DOMContentLoaded event is
       * fired when the document has been completely loaded and parsed.
       */
      function handleDomContentLoaded(event) {

      }

      /**
       * Handles the WebComponentsReady event. This event is fired when all
       * custom elements have been registered and upgraded.
       */
      function handleWebComponentsReady(event) {
        // Start the Ad lifecycle.
        setTimeout(function() {
          gwdAd.initAd();
        }, 0);
      }

      /**
       * Handles the event that is dispatched after the Ad has been
       * initialized and before the default page of the Ad is shown.
       */
      function handleAdInitialized(event) {}

      window.addEventListener('DOMContentLoaded',
        handleDomContentLoaded, false);
      window.addEventListener('WebComponentsReady',
        handleWebComponentsReady, false);
      window.addEventListener('adinitialized',
        handleAdInitialized, false);
    })();
  </script>
</body>
</html>